Therefore, no clinical parameter can be used to pre-select patients for EGFR TKI treatment.[6] It is recommended that all patients with NSCLC have their EGFR gene status determined before TKI therapy. This evidence concerns the gene EGFR and non-small cell lung carcinoma.